I don’t really enjoy saying I told you so but dammit…

look what the democrats dragged into our house now

https://wonder.cdc.gov/nndss/static/2024/09/2024-09-table460.html

Just make sure you read https://www.bucksafa11.org/2022/01/24/scientists-ya-cant-live-with-em/ before you start lining up for whatever they’re leading up to; at least it’s fact based UNadulterated opinion .

$*********$$$*********$

The morning after: I learn I was a day late and a dollar short once again.

…already approved this a few years ago.
https://en.wikipedia.org/wiki/Dengue_vaccine

Dengue vaccine is a vaccine used to prevent dengue fever in humans.[8] Development of dengue vaccines began in the 1920s, but was hindered by the need to create immunity against all four dengue serotypes.[9] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga.[10][11]

Dengvaxia is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected due to phenomenon known as antibody-dependent enhancement.[12] The value of Dengavaxia is limited by the fact that it may increase the risk of severe dengue in those who have not previously been infected.[13][12] In 2017, more than 733,000 children and more than 50,000 adult volunteers were vaccinated with Dengvaxia regardless of serostatus, which led to a controversy.[14] Qdenga is designated for people not previously infected.[15]

There are other vaccine candidates in development including live attenuated, inactivated, DNA and subunit vaccines.[9]

History

In December 2018, Dengvaxia was approved in the European Union.[6]

In May 2019, Dengvaxia was approved in the United States as the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages nine through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.[16][5] Dengue is endemic in the US territories of American Samoa, Guam, Puerto Rico, and the US Virgin Islands.[16]

The safety and effectiveness of the vaccine was determined in three randomized, placebo-controlled studies involving approximately 35,000 individuals in dengue-endemic areas, including Puerto Rico, Latin America and the Asia Pacific region.[16] The vaccine was determined to be approximately 76 percent effective in preventing symptomatic, laboratory-confirmed dengue disease in individuals 9 through 16 years of age who previously had laboratory-confirmed dengue disease.[16]

In March 2021, the European Medicines Agency the filing package for TAK-003 (Qdenga) intended for markets outside of the EU.[15]

In August 2022, the Indonesian FDA approved Qdenga for use in individuals six years to 45 years of age and become the first authority in the world to approve Qdenga.[17][18] Qdenga was approved in the European Union in December 2022.[7]